Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Ricursive Intelligence, a startup building an AI system to design and automatically improve AI chips, has raised $300 million at a $4 billion valuation. The company said Monday the round was led by ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...

In the first starred Times review from the islands, our critic finds intriguing twists on a cuisine that’s already fluid with Asian influences. Credit... Supported by By Ligaya Mishan Photographs and ...

Jan 10 (Reuters) - Elon Musk said on Saturday that social media platform X will open to the public its new algorithm, including all code for organic and advertising post recommendations, in seven days ...

Nintendo has said it was unwilling to backtrack on the design of Metroid Prime 4: Beyond's controversial open world hub despite seeing "changed" attitudes to open-world games, as the project had ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Instagram is introducing a new tool that lets you see and control your algorithm, starting with Reels, the company announced on Wednesday. The new tool, called “Your Algorithm,” lets you view the ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...